• Something wrong with this record ?

Rational Design of Self-Emulsifying Pellet Formulation of Thymol: Technology Development Guided by Molecular-Level Structure Characterization and Ex Vivo Testing

J. Macku, K. Kubova, M. Urbanova, J. Muselik, A. Franc, G. Koutna, M. Pavelkova, D. Vetchy, J. Masek, E. Maskova, J. Brus

. 2022 ; 14 (8) : . [pub] 20220725

Language English Country Switzerland

Document type Journal Article

Grant support
GA22-03187S Czech Science Foundation
MUNI/A/1251/2021 Masaryk University

The growing need for processing natural lipophilic and often volatile substances such as thymol, a promising candidate for topical treatment of intestinal mucosa, led us to the utilization of solid-state nuclear magnetic resonance (ss-NMR) spectroscopy for the rational design of enteric pellets with a thymol self-emulsifying system (SES). The SES (triacylglycerol, Labrasol®, and propylene glycol) provided a stable o/w emulsion with particle size between 1 and 7 μm. The ex vivo experiment confirmed the SES mucosal permeation and thymol delivery to enterocytes. Pellets W90 (MCC, Neusilin®US2, chitosan) were prepared using distilled water (90 g) by the M1-M3 extrusion/spheronisation methods varying in steps number and/or cumulative time. The pellets (705-740 μm) showed mostly comparable properties-zero friability, low intraparticular porosity (0-0.71%), and relatively high density (1.43-1.45%). They exhibited similar thymol release for 6 h (burst effect in 15th min ca. 60%), but its content increased (30-39.6 mg/g) with a shorter process time. The M3-W90 fluid-bed coated pellets (Eudragit®L) prevented undesirable thymol release in stomach conditions (<10% for 3 h). A detailed, ss-NMR investigation revealed structural differences across samples prepared by M1-M3 methods concerning system stability and internal interactions. The suggested formulation and methodology are promising for other lipophilic volatiles in treating intestinal diseases.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023671
003      
CZ-PrNML
005      
20221031095122.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics14081545 $2 doi
035    __
$a (PubMed)35893801
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Macku, Jan $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic $u Department of NMR Spectroscopy, Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic
245    10
$a Rational Design of Self-Emulsifying Pellet Formulation of Thymol: Technology Development Guided by Molecular-Level Structure Characterization and Ex Vivo Testing / $c J. Macku, K. Kubova, M. Urbanova, J. Muselik, A. Franc, G. Koutna, M. Pavelkova, D. Vetchy, J. Masek, E. Maskova, J. Brus
520    9_
$a The growing need for processing natural lipophilic and often volatile substances such as thymol, a promising candidate for topical treatment of intestinal mucosa, led us to the utilization of solid-state nuclear magnetic resonance (ss-NMR) spectroscopy for the rational design of enteric pellets with a thymol self-emulsifying system (SES). The SES (triacylglycerol, Labrasol®, and propylene glycol) provided a stable o/w emulsion with particle size between 1 and 7 μm. The ex vivo experiment confirmed the SES mucosal permeation and thymol delivery to enterocytes. Pellets W90 (MCC, Neusilin®US2, chitosan) were prepared using distilled water (90 g) by the M1-M3 extrusion/spheronisation methods varying in steps number and/or cumulative time. The pellets (705-740 μm) showed mostly comparable properties-zero friability, low intraparticular porosity (0-0.71%), and relatively high density (1.43-1.45%). They exhibited similar thymol release for 6 h (burst effect in 15th min ca. 60%), but its content increased (30-39.6 mg/g) with a shorter process time. The M3-W90 fluid-bed coated pellets (Eudragit®L) prevented undesirable thymol release in stomach conditions (&lt;10% for 3 h). A detailed, ss-NMR investigation revealed structural differences across samples prepared by M1-M3 methods concerning system stability and internal interactions. The suggested formulation and methodology are promising for other lipophilic volatiles in treating intestinal diseases.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kubova, Katerina $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic $1 0000000249702084
700    1_
$a Urbanova, Martina $u Department of NMR Spectroscopy, Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic
700    1_
$a Muselik, Jan $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic
700    1_
$a Franc, Ales $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic $1 0000000220274717
700    1_
$a Koutna, Gabriela $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic
700    1_
$a Pavelkova, Miroslava $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic
700    1_
$a Vetchy, David $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, 612 00 Brno, Czech Republic
700    1_
$a Masek, Josef $u Department of Pharmacology and Toxicology, Veterinary Research Institute, 621 00 Brno, Czech Republic $1 0000000167888487
700    1_
$a Maskova, Eliska $u Department of Pharmacology and Toxicology, Veterinary Research Institute, 621 00 Brno, Czech Republic
700    1_
$a Brus, Jiri $u Department of NMR Spectroscopy, Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic $1 000000032692612X
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 8 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35893801 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095120 $b ABA008
999    __
$a ind $b bmc $g 1853968 $s 1174959
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 8 $e 20220725 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a GA22-03187S $p Czech Science Foundation
GRA    __
$a MUNI/A/1251/2021 $p Masaryk University
LZP    __
$a Pubmed-20221010

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...